Zobrazeno 1 - 10
of 117
pro vyhledávání: ''
Autor:
Young Jin Suh, Young-Joo Lee, Jee Ye Kim, Ki-Tae Hwang, Chanheun Park, Jin Hyang Jung, Junwon Min, Seeyeong Kim
Publikováno v:
The Oncologist
Background We investigated the prognostic and predictive roles of the hormone receptor (HRc) subtype in patients with ductal carcinoma in situ (DCIS). We focused on identifying the roles of the progesterone receptor (PR) independent of estrogen recep
Autor:
Manuel Dómine Gómez, Tibor Csőszi, Rajesh K. Malik, Krasimir Nikolov, Iveta Kudaba, Davorin Radosavljevic, Jana Jaal, Janet K. Horton, Jie Xiao, Janakiraman Subramanian
Publikováno v:
International Journal of Cancer
Chemotherapy-induced myelosuppression is an acute, dose-limiting toxicity of chemotherapy regimens used in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemother
Autor:
Dooreh Kim, Jee Ye Kim, Byeong Woo Park, Seung Il Kim, Joon Jeong, Soong June Bae, Janghee Lee, Chihwan Cha, Hyung Seok Park, Soeun Park, Seho Park, Sung Gwe Ahn
Publikováno v:
International Journal of Cancer
Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into neoadjuvant systemic therapy (NST) led to higher response in patients with HER2‐positive breast cancer. However, axillary response to treatment regimens, including sin
Autor:
Sara A. Hurvitz, Maureen E. Trudeau, William J. Gradishar, Larisa Ryvo, Ming-Shen Dai, Sujith Kalmadi, Cristiano Souza, Eduardo Cronemberger, Suzette Delaloge, Adam Brufsky, Mafalda Oliveira, Vladimir Milovanov, Beverly Moy, Sung Bae Kim, Kiana Keyvanjah, J. Alarcón, Fairooz F. Kabbinavar, Ron Bose, Richard A. Bryce, Cristina Saura, Judith Bebchuk, Barbara Haley, Luciana Landeiro
Publikováno v:
The Oncologist
The oncologist, vol 26, iss 8
Scientia
The oncologist, vol 26, iss 8
Scientia
Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capeci
Autor:
Thomas M. O'Dorisio, Lowell Anthony
Publikováno v:
The Oncologist
Octreotide acetate (octreotide) is the most prescribed and most studied somatostatin congener, or analog, for gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) and carcinoid syndrome, the latter of which may be characterized by debilitating d
Autor:
Akihito Tsuji, Satoshi Kaihara, Michio Inukai, Takanori Watanabe, Toshihiko Matsumoto, Masahito Kotaka, Hiroki Hashida, Yasuhiro Miyake, Hiroaki Tanioka, Hisateru Yasui, Masato Matsuura, Shinichi Yoshioka, Yoshihiro Okita, Takeshi Kotake, Takahisa Kyogoku, Takeshi Kato, Hironaga Satake
Publikováno v:
The Oncologist
Lessons Learned Background The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3-month adjuvant treatment with capecita
Autor:
Hope S. Rugo, Stephen Chia, Wei-Chun Hsu, Juan Pablo Zarate, Hemanth Kanakamedala, David Chandiwana, Chu-Ling Yu, Jinhee Park, Antonia Ridolfi, Stuart J. Turner
Publikováno v:
The Oncologist
Background The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (AB
Autor:
Edward C. Stites, Steven C. Plaxe, Thomas McFall, Ramez N. Eskander, Kasey Bamel, Sadakatsu Ikeda, Barbara A. Parker, Shumei Kato, Razelle Kurzrock, Kenta Takahashi
Publikováno v:
The Oncologist
We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the di
Autor:
Shuvayu S Sen, Monika Raut, Dominique Lejeune, Guillaume Germain, François Laliberté, Philippe Armand, Xiaoqin Yang, Mei Sheng Duh, Kaushal Desai
Publikováno v:
The Oncologist
Background Diffuse large B‐cell lymphoma (DLBCL) represents the most common subtype of non‐Hodgkin lymphoma in the U.S., but current real‐world data are limited. This study was conducted to describe real‐world characteristics, treatment patte
Publikováno v:
Cytometry
The active metabolite of tamoxifen, 4‐hydroxytamoxifen, functions as an anti‐estrogen in breast cancer cells and thus inhibits proliferation. While tamoxifen continues to be successfully used to treat estrogen‐dependent breast cancer, most pati